Jens M Kittner1, Nora M Weiss2, Jörg Wiltink3, Jörg M Schattenberg2, Annette Grambihler2, Florian Thieringer2, Arndt Weinmann2, Tim Zimmermann2, Sandra Koch2, Marcus Schuchmann2, Peter R Galle2. 1. 1st Medical Department, Internal Medicine Department, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany. Electronic address: jens.kittner@unimedizin-mainz.de. 2. 1st Medical Department, Internal Medicine Department, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany. 3. Clinic of Psychosomatic Medicine and Psychotherapy, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Abstract
BACKGROUND: In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens. METHODS: Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012. RESULTS: 307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a higher degree of fibrosis was most strongly associated with a recommendation for treatment (OR 2.69), followed by the patients' demand (OR 2.27), presumed efficacy (OR 1.62), and tolerability (OR 1.58). A high risk of decompensation was associated with the decision to defer (OR 0.39). Speed of progression, compliance, extrahepatic manifestation, gender and age were not significantly related to the recommendation. Treatment was finally started in 101 patients (32.9%). CONCLUSION: In chronic genotype 1 hepatitis C, advanced fibrosis and patients' preference are the main rationales to choose treatment rather than deferral in a real-life setting.
BACKGROUND: In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens. METHODS: Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012. RESULTS: 307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a higher degree of fibrosis was most strongly associated with a recommendation for treatment (OR 2.69), followed by the patients' demand (OR 2.27), presumed efficacy (OR 1.62), and tolerability (OR 1.58). A high risk of decompensation was associated with the decision to defer (OR 0.39). Speed of progression, compliance, extrahepatic manifestation, gender and age were not significantly related to the recommendation. Treatment was finally started in 101 patients (32.9%). CONCLUSION: In chronic genotype 1 hepatitis C, advanced fibrosis and patients' preference are the main rationales to choose treatment rather than deferral in a real-life setting.
Authors: Donna M Evon; Carol E Golin; Teodora Stoica; Rachel E Jones; Sarah J Willis; Joseph Galanko; Michael W Fried Journal: Patient Date: 2017-06 Impact factor: 3.883
Authors: Philip Vutien; Michelle Jin; Michael H Le; Pauline Nguyen; Sam Trinh; Jee-Fu Huang; Ming-Lung Yu; Wan-Long Chuang; Mindie H Nguyen Journal: PLoS One Date: 2017-09-06 Impact factor: 3.240
Authors: Benjamin Schulte; Maximilian Wübbolding; Fiona Marra; Kerstin Port; Michael P Manns; David Back; Markus Cornberg; Dirk O Stichtenoth; Christoph Höner Zu Siederdissen; Benjamin Maasoumy Journal: Open Forum Infect Dis Date: 2020-02-03 Impact factor: 3.835